The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will wither -19.8% and EPS will wither -20.0%.
The average estimate for revenue is $109.0 million. On the bottom line, the average EPS estimate is $0.20.
Last quarter, ViroPharma logged revenue of $106.5 million. GAAP reported sales were 27% lower than the prior-year quarter's $145.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.10. GAAP EPS were -$0.09 for Q4 versus $0.65 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 71.6%, much worse than the prior-year quarter. Operating margin was -4.2%, much worse than the prior-year quarter. Net margin was -5.3%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $463.1 million. The average EPS estimate is $0.82.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,200 members out of 1,239 rating the stock outperform, and 39 members rating it underperform. Among 314 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 308 give ViroPharma a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is outperform, with an average price target of $32.81.
- Add ViroPharma to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.